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ABSTRACT 
 
Display technologies have demonstrated the utility of cyclic peptides as protein 
ligands, but cannot access proteins inside eukaryotic cells.  Expanding a novel 
chemical genetics tool, we describe the first expressed library of head-to-tail cyclic 
peptides in yeast.  We applied the library to selections in a yeast synucleinopathy 
model that recapitulates much of the cellular pathology of Parkinson’s disease.  
From a pool of five million transformants, we isolated two related cyclic peptide 
constructs which specifically reduce the toxicity of human α-synuclein.  These 
expressed cyclic peptides also prevent dopaminergic neuron loss in an established C. 
elegans Parkinson’s model.  This work highlights the speed and efficiency of using 
libraries of expressed cyclic peptides for forward chemical genetics in cellular models 
of human disease. 
  
Cyclic peptides (CPs) and their derivatives are potent bioactive compounds, and 
represent an underexplored, natural-product-like chemical space1,2.  Phage and RNA 
display have made it possible to screen large libraries of CPs, cyclized via disulfide bonds 
or other side chain linkages, to identify high-affinity ligands for nearly any in vitro 
target3,4.  By contrast, to date there are few methods for directly screening large libraries 
of CPs inside eukaryotic cells.  Such methods would provide several advantages over in 
vitro techniques, ensuring that hits are nontoxic, can bind their target(s) in the appropriate 
cellular environment, are not rapidly degraded by cellular proteases, and possess at least 
enough selectivity to function in living cells.  In addition, in vivo methods would enable 
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phenotypic selections of CPs, providing a more streamlined and less expensive alternative 
to traditional high-throughput screening with a greater chance of identifying effectors with 
non-traditional modes of action such as inhibition of protein-protein interactions. 
Recently, Benkovic and colleagues reported a promising method of generating 
libraries of head-to-tail CPs in vivo using a single genetic construct named SICLOPPS 
(split-intein-mediated circular ligation of proteins and peptides, Fig. 1A)5-7.  This 
construct uses a cleverly arranged split intein that splices out a linker region as a CP post-
translationally; the linker can be as small as four amino acids or as large as a whole 
protein8.  SICLOPPS-based CP libraries represent a powerful opportunity for rapid 
forward and reverse chemical genetics using in vivo selections7.  Previous work by 
Benkovic and colleagues interfaced expressed CP libraries with bacterial two-hybrid 
selections, an elegant strategy for reverse chemical genetics7.  Phenotypic screening of CP 
libraries was also performed in bacteria9,10.   Despite these successes, to date there has 
been only one reported attempt to adapt SICLOPPS libraries to a eukaryotic system.  A 
retroviral CP library was applied to a selection for inhibitors of interleukin-4 signaling in 
human B cells, yielding roughly a dozen CP pentamers with varying activity but no 
sequence consensus11.  The general utility of this library was hampered by its low actual 
diversity (2.7 x 105 members), the lack of quantitative quality assessment, and the several 
weeks required just to perform an initial round of selection. 
We sought to apply expressed CP libraries to eukaryotic cells and perform phenotypic 
selections in models of human disease in a rapid, efficient and generally applicable 
manner.  This goal dovetailed with our ongoing investigations of protein misfolding 
diseases, since we and others have postulated that targeting such diseases will require non-
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traditional modalities such as inhibition of protein-protein interactions or modulation of 
the proteostasis machinery12-14.  We therefore turned to CP libraries as a source of 
molecules most likely to act via these mechanisms, and to yeast models of protein 
misfolding diseases as testing platforms for this novel approach. 
We and others have demonstrated that, because protein misfolding often affects highly 
conserved biological pathways, complex diseases such as Parkinson’s disease (PD) can be 
modeled in simple organisms such as yeast15-20.  The human protein α-synuclein (α-syn) 
has been linked to Parkinson’s disease (PD) via genetic evidence and its prominence in 
the PD-associated intracellular aggregates known as Lewy bodies21-23.  α-syn is a small 
lipid-binding protein that is prone to misfolding and aggregation, and in the yeast 
Saccharomyces cerevisiae expression of human α-syn over a threshold level leads to ER 
stress, disruption of ER-Golgi vesicle trafficking, accumulation of lipid droplets, 
mitochondrial dysfunction, and ultimately cell death18-20.  This cellular pathology mirrors 
many aspects of dysfunction seen in neurons and glia of individuals with PD and other 
synucleinopathies23.  Genetic screening using our yeast synucleinopathy model has 
yielded suppressors of α-syn toxicity that are also effective in neuronal models19,20,24.  
Moreover, genetic analyses in these models have directly linked α-syn toxicity to the 
function of PARK9/ATP13A2, a protein whose mutations lead to an early-onset form of 
PD but otherwise had no known connection to α-syn24,25.  Thus, cellular models have been 
critical to our understanding of α-syn and its role in the selective degeneration of 
dopaminergic (DA) neurons in PD.  However, despite these and other intensive efforts, 
there remains a paucity of proven pharmacological targets for PD and other 
synucleinopathies. 
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Taking advantage of our established yeast synucleinopathy model, we constructed the 
first yeast-compatible CP library and used rapid phenotypic selections to isolate CPs that 
specifically reduce α-syn toxicity.  Further, we identified the CP motif responsible for 
activity and demonstrated that the selected CPs significantly reduce DA neuron loss in a 
C. elegans PD model.  These advances establish in vivo CP selections as an immediately 
useful tool for a broad range of biologists. 
 
RESULTS 
 
The SICLOPPS construct expresses and splices in yeast 
We obtained a SICLOPPS construct (a generous gift from Dr. Stephen Benkovic) and 
expressed it on a high-copy 2μ plasmid in Saccharomyces cerevisiae under a constitutive 
PGK promoter.  Lysates from log-phase and stationary-phase cultures were blotted using 
an antibody to a C-terminal tag (Fig. 1B), which revealed the expression level and splice 
status of the split intein construct8.  The log-phase cultures showed approximately equal 
amounts of 26 kDa and 20 kDa proteins, which are the expected sizes of the unspliced and 
spliced constructs, respectively.  Cultures harvested in stationary phase showed only the 
20 kDa band corresponding to the spliced form.  These findings are consistent with a 
splicing reaction that is somewhat slower than the rate of log-phase PGK-driven protein 
synthesis. 
A splice-disabled version of the gene was constructed by mutating the residues 
corresponding to T69 and H72 of the dnaE split intein to alanine.  Previous work has 
established that these mutations, which reside in conserved block B, permit association of 
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the two halves of the split intein but prohibit processing at the extein/N-intein junction.  
This blocks the first obligatory step in the accepted splicing mechanism26-28.  When a 
T69A/H72A mutant of the HPQ construct was expressed in yeast, only the full-length, 
unspliced form was detected (Fig. 1B).  Thus, the lower 20 kDa band indeed represents 
the expected product of intein splicing. 
To verify directly that the SICLOPPS construct produces CPs in yeast, we purified the 
encoded CP from yeast lysates by virtue of its HPQ motif.  This sequence has well-
established streptavidin affinity which was previously used to purify spliced CPs from 
bacterial cultures29.  We used streptavidin agarose to pull down the HPQ CP from lysates 
of stationary-phase yeast and confirmed its identity by MALDI and electrospray mass 
spectrometry (MW(M+H)=1330.6, MWobs=1330.5).  While the native yeast Vma1 intein has 
long been known and studied, these data provide the first demonstration that the 
SICLOPPS construct can be used to produce CPs in yeast. 
 
Construction of a yeast-compatible CP library 
Having established that the SICLOPPS construct expresses and splices in yeast, we 
sought to construct a high-diversity library compatible with yeast-based selections.  We 
used a previously described PCR cloning strategy consisting of PCR with a randomized 
oligonucleotide followed by a second PCR with constant primers to generate a 
randomized insert with a minimum of frameshift errors30.  In contrast to previous 
SICLOPPS libraries with smaller CP backbones, we chose to construct an octamer library 
to maximize diversity and minimize effects of side chains on splicing efficiency6,8,11. The 
library was designed to encode CP octamers with a single cysteine residue followed by 
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seven randomized residues, since a nucleophile at the first position is required for the 
transesterification step of intein processing 26.  DNA was randomized using the NNS 
codon scheme, where N is any nucleotide and S is guanine or cytosine.  This allows 
representation of all twenty amino acids while reducing the impact of degeneracy and stop 
codons.  After transformation into bacterial cells, the total diversity of the library (as 
measured by counting the number of independent transformants by serial dilution) was 5 x 
107 independent members. 
Library quality was assessed by picking and analyzing twenty colonies at random (Fig. 
1C and supplement).  Sequencing showed that library constructs encoded CPs with high 
diversity at the protein sequence level.  Sequence data also confirmed that the library 
possessed low background:  only one of twenty clones was the original HPQ-encoding 
vector, three of twenty possessed frameshift mutations, and one of twenty had a stop 
codon in the randomized region.  Thus, ~75% (15 of 20) of the library is estimated to 
encode novel CPs.  
We next assessed expression and splicing of each of the twenty randomly picked 
constructs.  The laboratory yeast strain W303 was individually transformed with each of 
the twenty constructs, grown to log phase, and lysed.  Western blots of these lysates 
revealed that all fifteen of the novel CP constructs expressed.  Fourteen showed evidence 
of some splicing at log phase, most of them quite robustly (Fig. 1C).  This quality control 
analysis indicates that roughly 70% of the library encodes CP constructs that express and 
splice in yeast, representing an overall real diversity of over thirty million CPs.  The 
library at least 0.1% of the overall theoretical diversity, and it represents a vast, diverse, 
and largely unexplored chemical space ready for screening or selection. 
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Selection in a yeast synucleinopathy model 
With a diverse, high-quality library in hand, we next sought to perform selections in a 
complex biological system, one which would not be amenable to in vitro methods such as 
phage display.  To this end, the library was applied to our yeast synucleinopathy model 
using a simple bulk selection protocol.  The yeast synucleinopathy model uses the GAL1 
promoter to tightly control expression of human α-syn, so that no α-syn is produced until 
the yeast are grown in galactose media18,19.  One liter of yeast culture was transformed 
with 80 μg library DNA and plated onto large library plates lacking uracil to select for 
transformed cells.  This yielded five million independent transformants, which were 
scraped, re-plated onto galactose media to induce α-syn expression, and incubated for 
three days (Fig. 2A).  Ninety-six large colonies were picked and the corresponding 
plasmids were isolated, amplified in bacteria, and tested by individually re-transforming 
each into the screening strain.  Thirty-one clones demonstrated reproducible suppression 
of α-syn toxicity in yeast, four of which are shown in Fig. 2B.  False positives likely 
stemmed from spontaneous genomic suppressor mutations, which are common in most 
yeast selections19,31. 
 
Filtering assays 
The thirty-one selected CP constructs were further evaluated using two secondary 
assays to exclude promoter effects and other nonspecific modes of action.  First, the 
constructs were transformed into a reporter yeast strain with the LacZ gene downstream of 
the GAL1 promoter32.  Expression of β-galactosidase from the GAL1 promoter was then 
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quantified using the soluble β-galactosidase substrate chlorophenol red-beta-D-
galactopyranoside (CPRG).  This enabled us to quantify the effects of each construct on 
GAL1-mediated expression independently of the presence of α-syn (Fig. 2C).  Second, the 
constructs were transformed into a yeast disease model that uses the GAL1 promoter for 
the inducible expression of a toxic polypeptide unrelated to α-syn, exon 1 of human 
huntingtin with 103 glutamine residues (Htt-103Q)16,17.  The transformants were then 
spotted onto galactose media to assess the abilities of selected hits to suppress the toxicity 
of Htt-103Q in yeast (Fig. 2D).  This assay provided a second check on whether the 
constructs acted by interfering with expression from the GAL1 promoter, and also tested 
whether the observed effects were specific to α-syn.  Of course, selected CP constructs 
that suppressed both α-syn and Htt-103Q toxicity could be affecting a pathway common 
to both33.  However, all selected constructs that prevented Htt-103Q toxicity also reduced 
GAL1-mediated expression (for example, CP3 shown in Fig. 2B-D).  Two of the thirty-
one selected constructs, denoted CP1 and CP2, suppressed α-syn toxicity but had no 
effects in the GAL1 reporter assay or on Htt-103Q toxicity, and thus act via an α-syn-
specific mechanism.  Notably, these results are in keeping with our previous results from 
genetic screens, in which genes that suppress α-syn toxicity possessed little overlap with 
genes that suppress Htt-103Q toxicity17,19.  Thus, suppressors such as CP1 and CP2 affect 
specific pathways of eukaryotic cell biology involved in the toxicity of these human 
proteins, rather than nonspecific pathways involved in general protection from misfolded 
or aggregated proteins.   
At this point we sought to ensure that the spliced CPs were responsible for the 
observed suppression of α-syn toxicity rather than nucleic acid or peptide aptamers 
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encoded by the selected constructs.  To this end, we performed three independent tests to 
ensure complete splicing was required.  We first tested T69A/H72A mutants of each 
construct, which are unable to process at the extein/N-intein junction26,27.  T69A/H72A 
mutants of CP1 and CP2 were unable to suppress α-syn toxicity (Fig. 2E).  Next, a 
different set of mutations at residues H24 and F26 in the dnaE C-intein domain 
(responsible for promoting asparagine cyclization in the final processing step at the 
extein/C-intein junction)26,34 were also shown to abolish the activities of CP1 and CP2 
(see supplement).  Thus, the complete splicing mechanism, including processing at both 
the N-intein and C-intein junctions, is required for CP1 and CP2 activity.  Finally, to 
completely rule out the possibility that linear peptide byproducts are responsible for 
suppression of α-syn toxicity, we also directly tested alternative constructs that represent 
products of an N-intein cleavage event rather than complete cyclization.  These constructs 
also failed to suppress α-syn toxicity, demonstrating that the sequences encoded by CP1 
and CP2 are inactive without complete intein splicing (see supplement for details).  
Remarkably, one of the strongest inhibitors of expression from the GAL1 promoter, CP3, 
also required splicing for function, demonstrating that its mode of action is also mediated 
by a spliced CP. 
 
Structure-activity relationships by point mutagenesis 
A critical bottleneck in chemical genetics is the generation of useful structure-activity 
relationship (SAR) data once hits are identified from large compound libraries.  SAR data 
are essential for understanding a molecule’s mode of action, for the development of more 
potent derivatives from initial hits, and for the derivatization of molecules as affinity 
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reagents.  A great advantage of the CP approach is that SAR data can be generated rapidly 
and cost-effectively using point mutagenesis.  The sequences of the CPs encoded by CP1 
and CP2 are shown in Figure 3A.  We generated a series of alanine-scanning mutants to 
identify which side-chains of CP1 and CP2 are responsible for function, and to determine 
whether the two suppressors share a common functional motif.  Each mutant was 
transformed into yeast and expression and splicing were verified by blotting log-phase 
cultures.  Yeast cells expressing each mutant were serially diluted and plated on galactose 
media to quantify the degree of α-syn toxicity suppression (Fig. 3B).  We found that the 
cysteine in the fourth CP position was absolutely required for activity in both constructs.  
Mutation of the hydrophobic residue in the third CP position (tryptophan for CP1 and 
leucine for CP2) resulted in constructs with very weak activity.  Mutation of the residue in 
the fifth CP position (serine for CP1 and glutamate for CP2) resulted in a slight but 
reproducible decrease (~5-fold) in growth, indicating a possible role for these side chains 
as well. 
Replacement of the cysteine in the first position with alanine resulted in another 
splice-disabled construct, rendering the mutant construct inactive (Fig. 3B).  To test the 
requirement for the first cysteine thiol in the spliced CP, we mutated it to serine.  These 
mutants expressed and spliced as efficiently as the original CP1 and CP2 constructs as 
assessed by blotting, but did not suppress α-syn toxicity (Fig. 3B).  Thus the cysteine in 
the first position is also required for the biological activities of selected CPs.  Overall, CP1 
and CP2 share a common CXΦC motif, wherein X is any residue and Φ is a hydrophobic 
residue; their functional motifs are highlighted in Figure 3A. 
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Minimization of the CP backbone using iterative design 
We constructed an octamer CP library to provide diversity, but it was unclear whether 
selected hits would be functional only as octamers or might be amenable to minimization.  
Minimization of CPs would evaluate the extent to which selected functional motifs are 
dependent on macrocycle size and structure, and would also be desirable for downstream 
applications as chemical genetics agents.  Having selected two functional CP constructs 
with a common tetrapeptide motif, we had the opportunity to test directly whether the 
remaining portions were necessary for proper orientation of the motif.  Thus, building 
upon our side chain SAR data, we designed further mutants in order to minimize CP ring 
size. 
CP1 proved especially amenable to minimization, as shown in Figure 3C.  Residue 8 
could be deleted entirely with no loss of function.  However, a construct with both 
residues 8 and 7 deleted showed only minimal function and a construct with residues 8, 7, 
and 6 deleted showed no ability to rescue α-syn toxicity.  Since the side chains of these 
residues are not required for function, we hypothesized that conformational effects on the 
CXΦC motif were responsible for the loss of function.  To restore proper orientation in 
the context of the hexamer, we tested a variety of substitutions in positions 2, 5 and 6, 
including glycine, alanine, proline, lysine, and tryptophan.  Of the twelve mutants tested, 
substitution of the threonine at position 6 with alanine or glycine had the greatest effect, 
restoring the ability to suppress α-syn toxicity to an extent comparable to that of the 
original eight-residue CP1 (Fig. 3C).  Splice-disabled mutants of these constructs were 
also tested to ensure that activity was still dependent on intein splicing.  Overall, two 
rounds of rationally designed mutagenesis generated constructs encoding CP hexamers 
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that suppress α-syn toxicity equally as well as the selected CP octamers CP1 and CP2.  
Thus, simple iterative testing of designed mutants was used to minimize the originally 
selected eight-residue CP (predicted MW=933) to a six-residue CP (predicted MW=634) 
with no observable change in in vivo activity. 
  
CP1 and CP2 are easily incorporated into affinity reagents 
Target identification is another notoriously difficult hurdle in forward chemical 
genetics35.  CPs are synthetically accessible in multi-milligram quantities and easily 
derivatized, making them ideal for physical pull-down experiments.  After verifying 
genetically that incorporation of a lysine at position 7 did not affect CP function (Fig. 3C), 
we synthesized CP1R7K and CP2W7K (see supplement).  Since the CPs have no free N-
termini, the lysine amines represent useful handles for site-specific derivatization or 
attachment to solid phase.  We linked the synthetic CPs to agarose beads and optimized 
pulldown conditions.  Notably, high lysate protein concentrations (5-10 mg/mL) could be 
used without extensive nonspecific binding due to the hydrophilic nature of the CPs. 
Proteins that selectively bound CP1 or CP2 beads over control CP-linked beads were 
eluted, separated by SDS-PAGE, and identified by mass spectrometry.  Yeast genetics 
greatly streamlines the process of validating potential targets, and so we were able to 
rapidly test several candidates including the chaperone proteins Ssa1 and Ssc1.  However, 
modulation of the levels of these proteins in yeast by genetic overexpression or deletion 
did not affect α-syn toxicity or CP-mediated suppression of α-syn toxicity.  We also 
easily linked CP1R7K and CP2W7K to biotin and to photoactivatable cross-linking groups, 
but were unable to selectively isolate additional target candidates.  There are three likely 
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explanations for these results.  First, CP targets may be transient, unstable, or present at 
low levels within the cell.  Second, selected CPs may possess low affinities for their 
targets, as CPs selected in bacteria showed high micromolar Ki’s and IC50’s in in vitro 
assays6,36.  Finally, CP1 and CP2 may act via a nontraditional mechanism that is 
incompatible with physical target identification (see discussion).  Our results demonstrate 
that the preparation of CP-based affinity reagents can be rapid and straightforward.  We 
are currently exploring further methods to translate this capability into similarly rapid 
techniques for target identification. 
 
CP1 and CP2 act in a manner that is distinct from known suppressors of α-syn 
toxicity 
Previous work using the yeast model has established that overexpression of human α-
syn affects multiple steps in vesicle trafficking20.  We wondered whether our selected CPs 
act upstream or downstream of this defect.  The yeast synucleinopathy model is 
particularly useful for examining the effects of α-syn on vesicle trafficking because α-syn 
induction can be tightly controlled and α-syn localization within the cell can be monitored 
in real time using YFP fusions19,20.  Shortly after induction, α-syn-YFP accumulates on 
the plasma membrane.  After 2-3 hours of α-syn-YFP induction, small foci are observed 
peripherally to the membrane, and after 4-6 hours these foci coalesce and begin to migrate 
inward toward the vacuole.  This latter stage is associated with the onset of cell death.  
Immunoelectron microscopy has revealed that these foci correspond to pools of stalled 
vesicles that are coated with α-syn-YFP20. 
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We wondered whether CP1 and CP2 prevent the accumulation of pools of stalled 
vesicles, since previously described genetic suppressors of α-syn toxicity mitigate the 
trafficking blockage19.  For instance, the expression of a Rab homologue involved in ER-
Golgi trafficking (Ypt1) or the yeast homologue of the P-type ATPase PARK9/ATP13A2 
(Ypk9) suppresses α-syn-YFP foci (Fig. 4A)19,20,24.  By contrast, CP1 and CP2 do not 
alter the occurrence or appearance of α-syn-YFP foci after 4 hours.  Electron microscopy 
confirms that cells co-expressing CP1 or CP2 along with α-syn still possess pools of 
stalled vesicles similar to those found in cells expressing a negative control CP along with 
α-syn (Fig. 4B).  Remarkably, even though 8-12 hours of α-syn-YFP induction is lethal to 
control cells, CP1 and CP2 possess α-syn-YFP foci continuously for over 48 hours after 
induction, with little change in appearance after 8 hours (Fig. 4A).  Thus, CP1 and CP2 
permit cells to grow and divide, albeit at a reduced rate, despite the continuous presence of 
stalled α-syn-coated vesicles.  This phenotype is unique among the genetic and small 
molecule suppressors of α-syn toxicity identified to date, and implies that selected CPs 
target a pathway downstream of established vesicle trafficking defects19,20,24,33. 
The previously described genetic suppressors Ypt1 and Ypk9 act in independent 
pathways, so that the simultaneous expression of both genes results in more potent 
suppression of α-syn toxicity than the expression of either gene by itself24.  To genetically 
test whether selected CPs act in a novel pathway, we expressed them in combination with 
Ypt1 or Ypk9.  The effects of CP1 and CP2 combine in an additive manner with the 
effects of either of these genetic suppressors (see supplement).  Thus, the CPs likely act in 
pathways that are distinct from those already linked to α-syn toxicity. 
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Expression of CPs in a metazoan animal model 
 We previously demonstrated that human homologues of suppressors of yeast α-syn 
toxicity identified were able to rescue dopaminergic (DA) neurons in animal models of 
synucleinopathy19,20.  In a Caenorhabditis elegans model, expression of human α-syn 
from the dopamine transporter promoter Pdat-1 results in degeneration of DA 
neurons20,37,38.  This enables direct evaluation of putative α-syn antagonists in DA neurons 
in the context of whole animals.  Nematode development is highly stereotyped and 
reproducible, so that any alteration in neuron quantity or morphology is highly significant.  
Nematodes are also transparent, enabling assessment and scoring of DA neurons in live 
animals by virtue of GFP expression under the control of the dat-1 promoter.  Using this 
model, we have found that expression of genes such as Rab1 and PARK9/ATP13A2 
(homologues of Ypt1 and Ypk9) ameliorate α-syn toxicity in the DA neurons of live 
animals20,24. 
We sought to evaluate whether CP1 and CP2 would similarly rescue DA neurons in 
the nematode synucleinopathy model.  Because the original split intein was isolated from 
a cyanobacterium, we first codon-optimized and re-synthesized the entire gene to ensure 
efficient expression in metazoan systems such as C. elegans and mammalian cells.  Then 
Pdat-1::mCP-gfp expression vectors were constructed by recombinational cloning with the 
pDEST-DAT-1 destination vector to generate a construct that would express the mCP 
gene with a C-terminal GFP fusion in nematode DA neurons. 
First, to verify that the mCP construct is expressed in the DA neurons of C. elegans, 
we injected Pdat-1::mCP-gfp expression vectors into wild-type animals.  Because 
nematodes have only eight DA neurons, detection of gene products expressed exclusively 
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in these few cells by Western blotting is problematic.  However, GFP fusions allow direct 
observation of protein expression in live animals.  Expression of mCP-GFP started during 
embryogenesis, and in adult animals robust GFP fluorescence was observed selectively in 
DA neurons (see supplement).  Because the GFP is encoded downstream of the mCP 
gene, we inferred that the mCP gene expresses in C. elegans DA neurons.  
 
CP1 and CP2 rescue DA neurons in a C. elegans synucleinopathy model  
We next tested the effects of expressed CP1 and CP2 on α-syn-mediated DA neuron 
loss in C. elegans.  The CP1 and CP2 sequences were introduced into mCP genes without 
GFP fusions by site-directed mutagenesis and the resulting constructs were cloned into the 
pDEST-DAT-1 vector19,20,24.  Transgenic worm lines were generated using these 
expression vectors as described19,38.  We also constructed and tested negative controls, 
denoted CP1* and CP2*, with the splice-disabling T69A/H72A mutation. 
We quantitated the effects of mCP constructs on α-syn toxicity as previously 
described for human and nematode genes, staging individual worms and inspecting the six 
anterior DA neurons (2 ADE and 4 CEP neurons)19,20,38.  Representative fluorescence 
micrographs of worms and population phenotype analyses are presented in Figure 5.  
Expression of all mCP constructs had no discernable effect on neuron health or 
morphology in the absence of α-syn, indicating the mCP gene is well-tolerated by live 
animals in DA neurons.  As previously described, GFP expression also had no effect on 
DA neurons, while α-syn expression caused striking DA neurodegeneration 19,20,24,38.  
Only 15% of 7-day old worms expressing α-syn retained wild-type numbers and 
morphologies of DA neurons.  Expression of mCP constructs encoding either CP1 or CP2 
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in these animals significantly reduced DA neurodegeneration, raising the proportions of 
animals devoid of neurodegeneration to 26% and 24%, respectively (Fig. 5G).  This 
degree of rescue is comparable to that observed with human Rab1, Rab3a or 
PARK9/ATP13A2 in the same system20,24.  Splice-disabled variants CP1* and CP2* were 
ineffective.   
We also quantitated the severity of the neurodegeneration by counting the number of 
healthy DA neurons in each animal studied.  We observed that 15% of animals expressing 
α-syn alone retained all six anterior DA neurons, while 40% retained five or more and 
80% retained four or more (Fig. 5H).  CP1 and CP2 significantly increased the proportion 
of worms with all six DA neurons intact and the proportion of animals that retained five or 
more DA neurons, consistent with our observations that worms expressing α-syn are most 
susceptible to degeneration in their two ADE neurons, and less susceptible in their four 
anterior CEP neurons20,24,38.  Animals expressing splice-disabled variants CP1* and CP2* 
showed similar distributions to those expressing α-syn alone, again demonstrating that 
intein processing is required for the observed activities of the CP1 and CP2 constructs.  
Overall, the amelioration of α-syn toxicity afforded by CP1 and CP2 matches those of 
endogenous regulators of PD-associated cellular pathways such as Rab1, Rab3a or 
PARK9/ATP13A220,24. 
 
DISCUSSION 
 
We report a rapid and versatile technique for the in vivo selection of bioactive CPs in 
yeast.  This technique represents a general chemical genetics strategy for identification of 
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functional modifiers of diverse cellular pathways.  Our CP octamer library encodes 
diverse macrocycles of molecular weights from ~600 to 1200 daltons and can be 
effectively introduced into any yeast strain, including models of human disease.  Hits can 
be rapidly identified using selections or screens that process millions of CPs in a single 
day without expensive robotics.  The genetic tractability of yeast ensures that diverse 
filtering assays can be applied in high-throughput fashion to isolate the most relevant and 
potent hits.  In selections using our yeast synucleinopathy model, two hits were isolated 
from an original pool of five million after only a single round of selection.  While 
additional rounds of selection were not required for selections in the synucleinopathy 
model, we note that multiple rounds of selection could be performed by pooling colonies 
and amplifying their plasmids en masse.  Stringency of the selection could be increased in 
subsequent rounds by using more robust selection conditions or by transferring selected 
CP genes to expression vectors with weaker promoters.   
We also report the first expression of optimized mCP genetic constructs in live 
metazoan animals.  Nematodes tolerate the construct well, with no observed effects on DA 
neuron health or morphology after lifelong expression of several different mCP 
constructs.  As in the yeast model, splice-disabled mutants were used to verify that the 
spliced CP, and not a nucleic acid or protein aptamer, was responsible for reducing α-syn 
toxicity.  The extents to which CP1 and CP2 reduce the amount and severity of DA 
neurodegeneration match those of human homologues of hits from our yeast genetic 
screen19.  These include Rab GTPases critical for proper vesicle trafficking and 
PARK9/ATP13A2, a putative P-type ATPase linked to a genetic, early-onset form of 
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parkinsonism19,20,24,25.  Thus, in yeast and C. elegans synucleinopathy models, selected 
CPs are as potent as endogenous regulators of key cellular pathways implicated in PD. 
The ability to use mutagenesis to generate SAR data and the straightforward synthesis 
of CPs greatly streamlines the turnaround of hits into affinity reagents for target 
identification.  The time from initial selections to having an affinity reagent in hand was 
less than two months.  Physical pull-downs have not yet revealed a clear target for CP1 
and CP2, but various alternatives are being employed to identify their modes of action.  
For instance, we are currently developing CPs with higher potency by designing more 
stringent selections and applying second-generation libraries that incorporate the CXΦC 
motif.  We are also exploring whether CP1 and CP2 reduce α-syn toxicity by buffering 
the thiol redox state of the cytosol or by otherwise altering the activity of thioredoxin-fold 
proteins39.  These possibilities are suggested by the striking similarity between the CXΦC 
motif and the thioredoxin-fold CXXC motif, the critical roles of thiol redox pathways in 
ER stress (which is a prominent effect of α-syn expression), and previous findings that 
dithiol small molecules, peptides and small CPs have biologically significant thiol redox 
potentials that vary greatly depending on neighboring functional groups and backbone 
conformation39-42.  The CXΦC motif may also function by binding metal ions, since metal 
ion transporters were discovered among the genetic suppressors and enhancers of α-syn 
toxicity and manganese exposure has long been known as a risk factor for PD-like 
syndromes24,43.  Either of these possibilities would represent novel proteostasis-based 
mechanisms that would defy physical target identification.  Finally, a variety of genetic 
and genomic tools are available for target identification in yeast, including transcriptional 
  21
profiling, genetic screening, and the use of libraries of bar-coded overexpression and 
deletion strains35,44.  All of these strategies will be applied to CP1 and CP2. 
CPs selected in the yeast synucleinopathy model produce an unexpected and unique 
phenotype, apparently acting downstream of α-syn-mediated vesicle trafficking defects.  
Moreover, CP1 and CP2 act independently of known genetic suppressors of α-syn 
toxicity, and are effective in both yeast and nematode synucleinopathy models.  This 
provides critical evidence that the target pathways are indeed conserved and relevant to 
the pathobiology of α-syn in neurons.  Whether they act by binding a specific protein or 
by modulating thiol or metal homeostasis, CP1 and CP2 represent a promising new 
avenue for the exploration of therapeutics for PD and other synucleinopathies.  Moving 
forward, the successful application of the new mCP construct in a metazoan animal opens 
the door to further validation in other PD models, including viral introduction into cell 
culture and incorporation in transgenic mice20,24,45. 
Overall, the CP approach represents an empowering technology for the rapid 
development of chemical genetics agents for systems that are difficult to address in vitro.  
In addition, the abundance of established yeast two-hybrid selection strains, already 
validated in explorations of the binary interactomes of yeast, C. elegans and man, will 
enable rapid and low-cost selections for CP inhibitors of specific protein-protein 
interactions at an unprecedented scale46-48.  Our approach provides a powerful alternative 
to traditional small molecule screening, straying from traditional “drug-like” chemical 
space but offering vastly higher throughput and lower cost.  It also possesses distinct 
advantages over display technologies, requiring fewer rounds of selection, obviating the 
need to purify and immobilize the target, and enabling selections in vivo, albeit with lower 
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throughput.  These trade-offs will appeal to biologists interested primarily in developing 
tools for probing specific cellular pathways and identifying key druggable proteins in 
disease models. 
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METHODS 
Yeast strains, manipulation, selections and blotting 
The α-syn-expressing yeast strains used in this study were all haploid W303 strains 
with the following genotype:  MATa can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 ade2-
1.  Selections and SAR data generation was performed in the previously described IntTox 
strain, which has human α-syn integrated using pRS303-αSynWT-YFP and pRS304-
αSynWT-YFP vectors19.  Co-expression of CPs with genetic suppressors was performed 
using the related HiTox strain, in which human α-syn is integrated using pRS304-
αSynWT-GFP and pRS306-αSynWT-GFP vectors18.  The Htt-103Q strain used was 
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similarly constructed from the W303 background using integrated pRS303-Htt103Q-GFP 
and pRS305-Htt103Q-GFP constructs as described16. 
Yeast cultures were transformed using standard lithium acetate heat shock.  In all 
cases, at least three independent transformants were isolated and tested to ensure 
reproducibility of the resulting phenotype.  Library transformations were performed using 
a scaled-up heat shock procedure.  One liter of IntTox yeast were grown to log phase in 
SC –his –trp media, pelleted and washed several times with water.  Pellets were 
resuspended in 20 mL of 0.1 M lithium acetate and incubated for 20 minutes at 30 °C with 
shaking.  Cells were then spun down and resuspended in 10 mLs of 0.1 M lithium acetate 
with 10 mM Tris-Cl, pH 7.5. 1 mM EDTA.  80 µg library DNA was added along with 1.4 
mLs of carrier DNA (salmon sperm DNA, 2 mg/mL, previously boiled and kept on ice) 
and 25 mLs of 50% PEG-4000.  After 30 minutes of incubation at 30 °C with shaking, 3 
mLs of DMSO was added and the cells were heat shocked at 42 °C for 23 minutes.  Cells 
were pelleted and resuspended in water prior to plating on large 24.5 x 24.5 cm Petri 
dishes of SC –his –trp –ura solid medium.  After two days, all colonies were scraped and 
pooled, and 150,000-200,000 cells were plated on each of 35 SGal –his –trp –ura plates.  
Picked colonies were cultured overnight in SC –ura and pelleted.  Plasmids were isolated 
using the PrepEase yeast plasmid isolation kit (USB). 
Cultures for blotting were produced by growing cultures until saturation (overnight), 
diluting to an OD600 of 0.1 and growing for 4-5 hours.  Lysates were produced by bead-
beating pelleted cells in ethanol with 1 mM phenylmethylsulphonyl fluoride (PMSF), 
removing the ethanol by evaporation in a Speed-Vac (Savant), and resuspending in 20 
mM Tris with 2% SDS.  These were then normalized by protein concentration using a 
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BCA assay (Pierce), mixed with SDS-free loading buffer and subjected to SDS-PAGE and 
blotting onto PVDF membranes.  Blotting was performed using anti-CBD serum (New 
England Biolabs) or anti-HA purified antibody (Sigma) according to standard protocols. 
 
HPQ cyclic peptide isolation 
Log-phase cultures expressing the HPQ-encoding SICLOPPS construct were spun 
down and resuspended in 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, with protease 
inhibitors (Roche) and 1 mM DTT.  Cells were lysed by passing through a French press at 
10,000 psi twice.  Lysates were incubated with streptavidin-agarose beads for 4 hours at 4 
°C and washed extensively.  1 mM biotin was used to elute the HPQ cyclic peptide.  
Eluates were freeze-dried using a Speed-Vac (Savant) and resuspended in 10 µL 
water/acetonitrile with 0.1% formic acid.  These were further cleaned using C18 ZipTips 
(Millipore) and analyzed by MALDI-MS (MW(M+H)=1330.6, MWobs=1330.5) as well as 
electrospray mass spectrometry (MW(M+H)=1330.6, MWobs=1330.6). 
 
Colorimetric LacZ assay in yeast 
Cells with a freshly integrated GAL1::LacZ construct were used to assess the effects of 
isolated CP constructs on expression from the GAL1 promoter32.  Samples were prepared 
by growing cells overnight in raffinose media, then diluting to an OD600 of 0.1 and 
growing for 4-8 hours in galactose media to induce LacZ expression.  Alternatively, cells 
were plated onto galactose plates and individual colonies were picked after 36-48 hours.  
Both methods produced similar results; data presented in Figure 2C are from picked 
colonies due to the ease with which many independent clones can be analyzed.  Cells were 
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spun down, washed with water, and normalized to an OD600 of 0.4-0.8 in 110 µL in wells 
of a 96-well plate.  90 µL of CPRG solution (100 mM HEPES, pH 7.25, 150 mM NaCl, 
0.65 mg/mL L-aspartate, 0.01 mg/mL BSA, 0.05% Tween, 0.5% SDS, 0.75 mg/mL 
chlorophenol red-beta-D-galactopyranoside (Sigma)) was added to each well.  Plates were 
shaken at room temperature for 30-120 minutes.  Plates were read at 578 nm and 
normalized for absorbance due to yeast optical density. 
 
C. elegans strain generation and analysis of DA neuron degeneration 
Nematodes were maintained following standard procedures49.  The transgenic strains, 
UA109 {baInl1[Pdat-1:: a-syn; Pdat-1::gfp]; baEx84[Pdat-1::mCP_CP1; rol-6 (su1006)]}, 
UA110 {baInl1[Pdat-1:: a-syn; Pdat-1::gfp]; baEx85[Pdat-1::mCP_CP1*; rol-6 (su1006)]}, 
UA111 {baInl1[Pdat-1:: a-syn; Pdat-1::gfp]; baEx86[Pdat-1::mCP_CP2; rol-6 (su1006)]}, 
UA112 {baInl1[Pdat-1:: a-syn; Pdat-1::gfp]; baEx87[Pdat-1::mCP_CP2*; rol-6 (su1006)]}, 
UA119 {vtIs1[Pdat-1::gfp; rol-6 (su1006)]; baEx93[Pdat-1::mCP_CP1; Punc-54::mCherry]}, 
UA120 {vtIs1[Pdat-1::gfp; rol-6 (su1006)]; baEx94[Pdat-1::mCP_CP1*; Punc-54::mCherry]}, 
UA121 {vtIs1[Pdat-1::gfp; rol-6 (su1006)]; baEx95[Pdat-1::mCP_CP2; Punc-54::mCherry]}, 
and UA122 {vtIs1[Pdat-1::gfp; rol-6 (su1006)]; baEx96[Pdat-1::mCP_CP2*; Punc-
54::mCherry]} were generated by directly microinjecting 50 ug/ml expression plasmids 
encoding cyclic peptide and 50 ug/ml rol-6 or Punc-54::mCherry marker into either the 
integrated UA44 {baInl1[Pdat-1:: a-syn; Pdat-1::gfp]} strain or the integrated BY200 
{vtls1[Pdat-1::gfp; rol-6 (su1006)]} as a control for toxicity50.  Three independent 
transgenic lines of worms were generated for each strain.  Age-synchronized worms were 
obtained and analyzed at the indicated time as described previously20,38.  The six anterior 
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DA neurons (4 CEP and 2 ADE neurons) of 30 animals per trial were examined for 
neurodegeneration when the animals were 7 days old.  After three trials, 90 animals for 
each line were analyzed, making a total of 270 worms analyzed for each transgenic strain.  
If a worm displayed at least one degenerative change (dendrite or axon loss, cell body 
loss), the animal was scored as exhibiting degenerating neurons37,38.  For each trial, 30 
worms were transferred onto a 2% agarose pad, immobilized with 2 mM levamisole, and 
analyzed using Nikon Eclipse E800 epifluorescence microscope equipped with Endow 
GFP HYQ filter cube (Chroma Technology, Rockingham, VT). Images were captured 
with a Cool Snap CCD camera (Photometrics, Tucson, AZ) driven by MetaMorph 
software (Universal Imaging, West Chester, PA). 
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FIGURE LEGENDS 
 
Figure 1.  A cyclic peptide library that expresses and splices in yeast.  (A) The 
SICLOPPS (split-intein mediated circular ligation of peptides and proteins) construct, 
designed by Benkovic and colleagues, encodes a single protein construct that yields a 
cyclic peptide (CP) after post-translational splicing.  The dnaE intein C-terminal domain 
is encoded first, followed by the linker to be cyclized, the intein N-terminal domain, and 
finally a chitin binding domain affinity tag (not shown).  Graphic was generated using the 
crystal structure of the post-splicing form of the Synechocystis Sp. PCC6803 dnaE intein, 
PBD ID 1ZD7 28. (B) Western blots against the affinity tag detect the presence and the 
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splicing state of the split intein construct.  Log-phase yeast cultures expressing the control 
HPQ construct (HPQlog) show robust expression and roughly 50% distribution between 
the unspliced 26 kDa construct and the spliced 20 kDa byproduct.  Yeast blotted at 
stationary phase (HPQstat) show complete splicing, while an HPQ variant with splice-
disabling T69A/H72A mutations (HPQ*) shows no spliced byproduct in log phase.  (C) 
Blots of log-phase cultures of yeast transformed with 20 randomly picked library 
members demonstrate that roughly 70% of the library encodes novel CP constructs that 
express and splice in yeast. 
 
Figure 2.  Identification of two CPs that selectively reduce α-syn toxicity in yeast.  
(A) The α-syn selection strain was transformed with the CP library, allowed to recover, 
and re-plated on galactose media to induce α-syn expression.  Glucose and galactose 
plates are shown to highlight how a single robust hit clone could be isolated from 
>150,000 cells on a single plate.  (B) Following isolation and amplification in bacteria, hit 
plasmids were individually transformed into the screening strain.  Transformants were 
allowed to recover, normalized for cell number, serially diluted, and plated on galactose 
media.  Four hits, named CP1-4, are shown along with a negative control CP plasmid 
(HPQ) and the positive control Mig1, a genetic repressor of the GAL1 promoter. (C) A 
GAL1-LacZ reporter assay using the soluble β-galactosidase substrate chlorophenol red-
beta-D-galactopyranoside (CPRG) demonstrates that CP1 and CP2 do not affect protein 
expression.  Error bars show standard deviation from five independent trials.  (D) Spotting 
assay, similar to (B), demonstrating that CP1 and CP2 do not affect toxicity in a yeast 
strain expressing multiple copies of Htt-103Q using the GAL1 promoter.  (E) Spotting 
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assay, similar to (B), demonstrating that splice-disabled T69A/H72A mutants of CP1-3 
(denoted with asterisks) no longer suppress α-syn toxicity.  Thus, for these constructs both 
specific CP sequences and intein processing are required for activity. 
 
 
Figure 3.  Rapid generation of structure-activity relationship (SAR) data and 
rapid minimization using point mutagenesis.  (A) Sequences of the CPs encoded by 
CP1 and CP2.  Residues found by SAR analysis to be required for function are shown in 
red, and residues with minor contributions are shown in pink. (B) Spotting assays of 
normalized, serially diluted cells of the screening strain expressing the negative control 
HPQ, the selected construct CP1, indicated point mutants of CP1, and the splice-disabled 
T69A/H72A mutant CP1*.  Each construct was verified to express and splice in yeast.  
Similar results were obtained for CP2 and are presented in the supplement.  (C)  Spotting 
assays of yeast expressing HPQ, CP1, and additional CP1 variants.  These variants 
illustrate incorporation of a chemical handle (here lysine substitution at position seven) as 
well as minimization of the encoded CP.  Each construct was verified to express and 
splice in yeast.  Asterisks denote splice-disabled T69A/H72A mutants, which were 
verified to express but not splice. 
 
 
 Figure 4 – Selected CPs operate downstream of known vesicle trafficking defects.  
(A) Representative fluorescence micrographs of cells expressing α-syn-YFP after 4 hours 
(first row) or 48 hours (second row), along with the indicated CP or yeast gene.  (B) 
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Representative electron micrographs of cells expressing α-syn-YFP after 4 hours, along 
with the indicated CP.  m = mitochondrion, n = nucleus, v = vacuole, and arrows highlight 
pools of stalled vesicles.  White ovals are lipid droplets. 
 
Figure 5 – Selected CPs reduce α-syn-mediated toxicity in C. elegans DA neurons.  
(A-F) Representative fluorescence micrographs of isogenic worm strains with GFP 
expression in DA neurons.  Cell bodies are indicated by arrowheads, with processes 
visible to the right.  (A,B) At the 7 day-old stage, worms exhibit 6 intact anterior DA 
neurons.  However, most worms expressing α-syn have missing or degenerated anterior 
DA neurons. (C,D) Expression of CP1 in anterior DA neurons had no discernable effect 
on neuron health or development in the absence of α-syn.  CP1 protected the DA neurons 
from α-syn-induced neurodegeneration, resulting in a greater proportion of worms with no 
degeneration in all 4 CEP and 2 ADE neurons. (E,F) Expression of the splice-disabled 
CP1* construct also had no effect on DA neurons in the absence of α-syn, but CP1* does 
not afford the same protection as CP1.  (G) Population analysis revealed that 26% and 
24% of worms expressing CP1 and CP2 showed no neurodegeneration, respectively, 
compared with only ~15% of control worms expressing only a-syn or expressing splice-
disabled constructs CP1* and CP2* (**indicates p<0.05, student’s t-test). Error bars show 
standard deviations of three trials with three independently generated worm lines, n=90 
for each line, making a total of 270 animals examined for each transgenic strain. (H) 
Distributions of worms by number of intact, wild-type DA neurons reveals that selected 
CPs also reduce the severity of the observed neurodegeneration, preferentially rescuing 
the two more sensitive ADE neurons. 





